2019
DOI: 10.2147/ott.s207546
|View full text |Cite
|
Sign up to set email alerts
|

<p>Novel cancer therapy targeting microbiome</p>

Abstract: In the human intestinal tract, there are more than 100 trillion symbiotic bacteria, which form the gut microbiota. Approximately 70% of the human immune system is in the intestinal tract, which prevents infection by pathogenic bacteria. When the intestinal microbiota is disturbed, causing dysbiosis, it can lead to obesity, diabetes mellitus, inflammatory bowel disease, rheumatoid arthritis, multiple sclerosis, autism spectrum disorder and cancer. Recent metabolomics analyses have also made the association betw… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

2
24
0
1

Year Published

2019
2019
2023
2023

Publication Types

Select...
8
2

Relationship

0
10

Authors

Journals

citations
Cited by 33 publications
(27 citation statements)
references
References 73 publications
(55 reference statements)
2
24
0
1
Order By: Relevance
“…Recently, the physiological and pathological roles of gut microbiota have garnered great interest. Research has shown how they affect systematic metabolism, inflammation, and the immune system, contributing to carcinogenesis, malignant potential, and cancer progression, of which similar findings have been reported in UC [108][109][110]. Interestingly, SFN was found to normalize gut microbiota dysbiosis by increasing the abundance of Bacteroides fragilis and Clostridium cluster I in a BBN-induced BC animal model [111], suppressing BBN-induced histological changes, including sub-mucosal capillary growth.…”
Section: In Vitro Studies: Inflammation Epithelial-to-mesenchymal Trsupporting
confidence: 59%
“…Recently, the physiological and pathological roles of gut microbiota have garnered great interest. Research has shown how they affect systematic metabolism, inflammation, and the immune system, contributing to carcinogenesis, malignant potential, and cancer progression, of which similar findings have been reported in UC [108][109][110]. Interestingly, SFN was found to normalize gut microbiota dysbiosis by increasing the abundance of Bacteroides fragilis and Clostridium cluster I in a BBN-induced BC animal model [111], suppressing BBN-induced histological changes, including sub-mucosal capillary growth.…”
Section: In Vitro Studies: Inflammation Epithelial-to-mesenchymal Trsupporting
confidence: 59%
“…In recent years, the relationship between gut microbiota and multiple diseases has attracted much attention. The role of gut microbiota on gastric cancer has also been investigated [104,105]. A study revealed that microbiota might be related to gastric cancer, since specific pathogen-free mice were easier to develop atrophic gastritis and gastric cancer than germ-free mice [106].…”
Section: Modulation Of Gut Microbiotamentioning
confidence: 99%
“…Several strategies can be considered in order to improve the efficacy of cancer treatment through gut microbiota modulation [9,103,104]. While targeting the gut microbiome has shown some interesting results in the treatment of cancers, the studies demonstrated that improved effects of cancer therapies following microbiota modulation are much more limited [105]. In this second part of the review, we focused on the potential strategies to optimize the microbiota composition in order improve therapy efficiency.…”
Section: Modulation Of the Gut Microbiome To Enhance Therapy Efficmentioning
confidence: 99%